Generic Product News

Published Online: Thursday, January 13, 2011

Donepezil Hydrochloride Orally Disintegrating Tablets
Marketed By:
Teva Pharmaceuticals (North Wales, PA)
Compared to: Aricept ODT (Eisai Inc)
Indication: Teva announced the FDA approval and launch of donepezil hydrochloride orally disintegrating tablets, the AB-rated generic equivalent to Eisai’s Aricept ODT. Teva’s product is indicated for the treatment of dementia in patients with mild, moderate, and severe Alzheimer’s disease. A typical dosage is 5 to 10 mg, administered once daily, for mild to moderate Alzheimer’s disease. Patients with severe Alzheimer’s disease should graduate to a dose of 10 mg after taking a daily dose of 5 mg for 4 to 6 weeks.
Dosage Form: Orally disintegrating Tablets: 5 and 10 mg
For More Information:; 888-838-2872 66 n 01.11


Amlodipine Besylate and Benazepril Hydrochloride Capsules
Marketed by:
Par Pharmaceutical Companies (Woodcliff Lake, NJ)
Compared to: Lotrel (Novartis)
Indication: Par Pharmaceutical received FDA approval for amlodipine besylate and benazepril hydrochloride capsules, the generic version of Novartis’ Lotrel. The capsules contain amlodipine besylate, a calcium channel blocker, and benazepril, an angiotension-converting enzyme (ACE) inhibitor. Amlodipine besylate and benazepril hydrochloride capsules are indicated for the treatment of hypertension in patients not adequately controlled on monotherapy with either agent. They are contraindicated in patients with a history of angioedema (with or without previous ACE inhibitor treatment), or patients who are hypersensitive to benazepril, to any other ACE inhibitor, or to amlodipine, and should be discontinued if pregnancy is detected.
Dosage form: Capsules: 2.5/10, 5/10, 5/20, 10/20, 5/40, and 10/40 mg
For More Information:; 201-802-4000

Mefenamic Acid Capsules
Marketed by:
Paddock Laboratories (Minneapolis, MN)
Compared to: Ponstel (Shionogi Pharma)
Indication: The FDA approved Paddock’s mefenamic acid capsules, a generic version of Shionogi Pharma’s Ponstel. Mefenamic acid is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the relief of mild to moderate pain in patients older than 14 years, as well as for the treatment of primary dysmenorrhea. Patients taking mefenamic acid capsules should be aware of the potential cardiovascular side effects and GI discomfort associated with NSAIDs. Mefenamic acid capsules should be taken at the lowest dose and for the shortest duration needed, and treatment should not exceed 7 days.
Dosage Form: Capsules: 250 mg
For More Information:; 800-328-5113


Levocetirizine Dihydrochloride Tablets
Marketed by:
Perrigo Pharmaceuticals (Allegan, Michigan)
Manufactured by: Synthon Pharmaceuticals
Compared to: Xyzal (UCB/Sepracor and sanofi-aventis)
Indication: Perrigo and Synthon announced the approval and launch of levocetirizine dihydrochloride tablets, a generic version of Xyzal tablets, which are manufactured by UCB/Sepracor and marketed in the US by sanofi-aventis. Levocetirizine is an antihistamine indicated for the relief of symptoms associated with seasonal and perennial allergic rhinitis and chronic hives. Levocetirizine tablets are available as immediate release 5-mg scored tablets, which can be broken in half to administer a 2.5- mg dose, if needed. The recommended dose is 1 tablet, taken once daily in the evening.
Dosage Form: Tablets: 5 mg
For More Information:; 269-673-8451

Latest Articles
Donnie Calhoun, RPh, PD, National Community Pharmacists Association (NCPA) Foundation vice president, discusses how pharmacists can prepare themselves and their business before, during, and after a disaster.
Ken Whittemore Jr, Surescript's senior vice president of professional and regulatory affairs, talks about some new transactions available that can help pharmacists.
In case you got caught up in the Thanksgiving holiday rush, here are the top trending stories you may have missed in November:
Bryan Ziegler, PharmD, executive director of Kennedy Pharmacy Innovation Center, provides some resources for community pharmacists to use when implementing new collaborative services with primary care providers.
Latest Issues